Besides, reduced appetite, anorexia and altered intestinal motility often accompany intestinal inflammation, and might be linked to EEC, since PYY, GLP-1, and CCK signal satiety and modify motility (163, 164)
in misuse scenarios, cardiomegaly has been reported
Certain individuals may be at greater risk of experiencing skin side effects
They found that people were most likely to reduce their consumption of certain food groups, such as soft drinks and beef
The meta-analysis further broke down how common nausea is for the five FDA-approved GLP-1 drug types, and another study looked at tirzepatides rate: Dulaglutide: 5-29% Exenatide: 5-59% Liraglutide: 10-48% Lixisenatide: 16-40% Semaglutide: 8-58% Tirzepatide: 20.43% Youll notice that these percentages vary quite a bit
Obesity, hypertriglyceridemia, and metabolic syndromeconditions commonly present in patients prescribed GLP-1 agonistsare themselves established risk factors for pancreatic inflammation